Mandate

Vinge advises Cinclus Pharma in connection with a capital raising

Vinge has advised the pharmaceutical development company Cinclus Pharma in connection with a capital raising of approximately SEK 250 million by way of a directed share issue to several new investors and current shareholders.

The purpose of the share issue is to fund the further clinical development of X842, a clinical-stage drug candidate for the treatment of gastroesophageal reflux disease (GERD).

Vinge’s team consisted primarily of Dain Hård Nevonen, Kristina Ekberg, Amanda Knutsson and Fredric Reissmüller.

Related

Vinge has advised KLAR Partners in connection with its divestment of Swoosh Group to Serwent

Swoosh is a leading provider of inspection, maintenance, and services for underground infrastructure in Sweden, delivering sewer pipe inspection, cleaning, repair, and maintenance to municipalities, industrial operators, and property owners across 23 sites nationwide. Swoosh today employs approximately 450 people and generates revenues of nearly SEK 700 million.
August 13, 2026

Vinge has advised Montrose by Carnegie AB on its application for authorisation to conduct securities business

Vinge has successfully advised Montrose by Carnegie AB in connection with its application to the Swedish Financial Supervisory Authority for authorisation to conduct securities business. The authorisation was granted by the Swedish Financial Supervisory Authority on 2 July 2026.
August 12, 2026

Vinge advises Mjällby AIF on the transfer of Elliot Stroud to Hull City AFC

Vinge has advised reigning Allsvenskan champions Mjällby AIF in connection with the transfer of Swedish international Elliot Stroud to Premier League club Hull City AFC.
August 10, 2026